Patent · US Active

Amphotericin B derivative with reduced toxicity

US9738677B2 · kind B2 · utility

2Cited by

0References

9Claims

0Family size

Assignee

The Board of Trustees of the University of Illinois · US

Inventors

Martin D. Burke · Champaign, US
Brice E. Uno · Champaign, US

Key dates

Filing date	May 15, 2015
Grant date	Aug 22, 2017
Priority date	—
Expiry date	May 15, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed is a derivative of amphotericin B (AmB), denoted C2′epiAmB, with an improved therapeutic index over amphotericin B, pharmaceutical compositions comprising the AmB derivative, methods of making the AmB derivative and the pharmaceutical composition, and their use in methods of inhibiting growth of a yeast or fungus and treating a yeast or fungal infection. C2′epiAmB is an epimer of the parent compound. Specifically, C2′epiAmB differs from the parent compound at the C2′ stereogenic center on mycosamine. This difference in structure results in (i) retained capacity to bind ergosterol and inhibit growth of yeast, (ii) greatly reduced capacity to bind cholesterol, and (iii) essentially no toxicity to human cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.